Immunic's lead asset, vidofludimus calcium, shows promise in MS trials, with positive interim results. See why I rate IMUX ...

Antev Shareholders to Receive Aggregate ~19% Equity Stake in Medicus, Plus US$65 Million in Contingent Payments Antev is developing Teverelix, A next generation ...

Unrepresentative pre-clinical models contribute to poor translation of glioblastoma research. We present an ...

Scientific studies validate breathwork's role in reducing anxiety and stress, highlighting its effectiveness in promoting ...

President Trump's second term, DOGE hasn't delivered on its promised savings, efficiency or transparency in meaningful ways.

If your current reaction to recent market volatility is to expect it to continue indefinitely, you will likely be ...

(NASDAQ: REGN) today announced that the European Commission (EC) has granted conditional marketing approval of Lynozyfic™ (linvoseltamab) to treat adults with relapsed and refractory (R/R) multiple ...

While technology may continue to be an excellent investment and repeat its outstanding returns of the past five years, the ...

Behind the seeming chaos of Trump’s tariff policy, there’s a coherent plan to reboot what Peter Gowan dubbed the “Dollar–Wall ...